Reuters logo
BRIEF-Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma
May 2, 2017 / 12:21 PM / 5 months ago

BRIEF-Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma

May 2 (Reuters) - Bluebird Bio Inc

* Bluebird bio inc- entered into a worldwide license agreement around its proprietary lentiviral vector platform with novartis pharma ag

* Bluebird bio inc- financial terms of agreement with novartis include an upfront payment to bluebird as well as milestone and royalty payments

* Bluebird bio-under terms novartis to non-exclusively license certain of co’s patent rights to develop, commercialize chimeric antigen receptor t cell therapies for oncology Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below